Human-to-Veterinary Drug Repurposing: Policy Pathways and Market Opportunities in 2026

Introduction

The global veterinary pharmaceuticals market reached $37.01 billion in 2026, growing at a compound annual growth rate of 6.0%^[1], yet the development of new veterinary drugs remains significantly slower and more expensive than repurposing existing human medications. Drug repurposing—the strategic redirection of approved human pharmaceuticals for veterinary applications—offers a faster, more cost-effective pathway to address unmet medical needs in companion and food-producing animals. With the China veterinary medicine market alone projected to grow from $5.11 billion in 2026 to $9.29 billion by 2032^[2], pharmaceutical manufacturers face unprecedented opportunities to leverage existing drug portfolios for veterinary applications.

Aligned Machinery, a premium supplier of pharmaceutical manufacturing equipment serving the global pharmaceutical industry, recognizes the critical role that efficient production technology plays in facilitating the human-to-veterinary drug transition. This article examines the regulatory pathways, scientific considerations, and commercial opportunities that define the drug repurposing landscape in 2026, providing pharmaceutical manufacturers and equipment suppliers with actionable insights for navigating this growing market segment.

Quick Answer: What Are the Main Pathways for Human-to-Veterinary Drug Repurposing?

Three primary regulatory pathways enable human-to-veterinary drug repurposing: the New Animal Drug Application (NADA) process in the United States, the EU Regulation 2019/6 framework in Europe, and off-label veterinary use under the Animal Medicinal Drug Use Clarification Act (AMDUCA). Each pathway requires different levels of documentation, species-specific safety and efficacy data, and manufacturing adjustments. The NADA process typically requires 3–5 years compared to 10–15 years for de novo drug development^[3], while EU pathways demand comprehensive gap analyses comparing human medicinal product (HMP) dossiers with veterinary medicinal product (VMP) requirements^[4].

Regulatory Pathways Comparison: US, EU, and Global Frameworks

Understanding the Drug Repurposing Advantage

Why Repurpose Human Drugs for Veterinary Use?

Drug repurposing reduces development costs by 40–60% and accelerates time-to-market by 5–10 years compared to de novo drug development^[3]. The capitalized cost of developing a new human drug reached $2.558 billion in 2013^[3], while repurposing existing compounds with established safety profiles significantly reduces preclinical and early clinical trial requirements. For veterinary applications, this cost advantage becomes even more pronounced due to smaller market sizes that make de novo development economically unfeasible.

The companion animal drugs market, valued at $28.8 billion in 2026 and projected to reach $51.1 billion by 2035^[5], demonstrates the commercial viability of veterinary drug repurposing. Pharmaceutical manufacturers can leverage existing manufacturing infrastructure, regulatory knowledge, and safety databases to enter this growing market with reduced risk and investment.

Scientific Basis for Cross-Species Drug Application

Approximately 80% of human drugs share similar pharmacological mechanisms with potential veterinary applications^[3], particularly in areas such as oncology, pain management, cardiovascular disease, and infectious disease treatment. The biological similarity between humans and companion animals—especially dogs and cats—enables effective translation of therapeutic mechanisms. COX-2 inhibitors, originally developed for human arthritis and pain management, have been successfully repositioned for canine cancer treatment, demonstrating both anti-inflammatory and anti-tumor properties in veterinary applications^[3].

However, species-specific differences in drug metabolism, dosing requirements, and toxicity profiles necessitate careful evaluation. Certain excipients commonly used in human medicinal products may be toxic to specific animal species and require formulation adjustments^[4].

US FDA Regulatory Pathway for Veterinary Drug Repurposing

New Animal Drug Application (NADA) Process

The FDA Center for Veterinary Medicine (CVM) oversees the NADA process, which requires demonstration of safety and effectiveness for the intended animal species, proper labeling, and manufacturing under current Good Manufacturing Practices (cGMP). The process begins with an Investigational New Animal Drug (INAD) exemption, allowing sponsors to conduct research studies before formal application submission.

Key NADA Requirements for Repurposed Human Drugs:

1. Target Animal Safety Studies — Species-specific toxicology data demonstrating safe dose ranges for the intended animal population
2. Effectiveness Studies — Clinical trials proving therapeutic benefit in the target animal species under field conditions
3. Human Food Safety — For food-producing animals, establishment of withdrawal periods and tolerance levels to ensure human food safety
4. Chemistry, Manufacturing, and Controls (CMC) — Formulation adjustments for veterinary administration, stability data, and manufacturing process validation
5. Environmental Impact — Assessment of environmental effects from animal excretion and waste disposal

Abbreviated New Animal Drug Application (ANADA)

Generic veterinary drugs can be approved through the ANADA pathway, requiring only bioequivalence demonstration to an already-approved veterinary drug, reducing approval time to 1–2 years. This pathway becomes available after the innovator’s data exclusivity period expires, offering cost-competitive entry for manufacturers with established production capabilities.

Aligned Machinery’s pharmaceutical manufacturing equipment supports the transition from human to veterinary drug production by providing flexible, GMP-compliant systems that accommodate formulation modifications, dosage adjustments, and species-specific packaging requirements essential for ANADA compliance.

EU Regulatory Framework: Regulation 2019/6

Comprehensive Gap Analysis Requirement

EU Regulation 2019/6, which came into full effect in 2022, establishes a comprehensive framework for veterinary medicinal products that differs significantly from human drug regulations in areas such as CMC, pharmacovigilance, and environmental risk assessment^[4]. Pharmaceutical companies transitioning from human to veterinary products must conduct detailed gap analyses comparing existing HMP dossiers with VMP requirements.

Critical Differences Between HMP and VMP in the EU:

• Environmental Risk Assessment (ERA) — VMP requires more comprehensive ERA due to direct environmental release through animal excretion, evaluating impacts on soil, water, and non-target organisms^[4]
• Maximum Residue Limits (MRLs) — Food-producing animals require establishment of MRLs to ensure drug residues in animal products remain safe for human consumption^[4]
• Formulation Considerations — Excipient toxicity profiles differ across species; palatability, taste, smell, and texture must be optimized for animal administration^[4]
• Pharmacovigilance Systems — Separate Pharmacovigilance System Master File (PSMF) required for veterinary products, with species-specific adverse event reporting and different timelines^[4]

Marketing Authorization Routes

Three primary marketing authorization routes exist in the EU: centralized procedure (mandatory for biotechnology-derived products), decentralized procedure (simultaneous application in multiple member states), and national procedure (single member state). The choice depends on market strategy, product characteristics, and regulatory complexity.

Manufacturing and Formulation Adjustments

Species-Specific Formulation Optimization

Successful human-to-veterinary drug repurposing requires formulation modifications addressing species-specific physiology, administration routes, and palatability requirements. Dogs and cats have different taste receptors than humans, requiring flavor masking or palatability enhancers. Large animals such as horses and cattle need different dosage forms—often boluses, pastes, or pour-on formulations—compared to human tablets or capsules.

Critical Formulation Considerations:

1. Excipient Safety — Propylene glycol is safe for humans but toxic to cats; xylitol is safe for humans but highly toxic to dogs^[4]
2. Dose Variation — Weight-based dosing requires flexible formulation strengths or easily divisible dosage forms
3. Administration Method — Oral, topical, injectable, and transdermal routes require different formulation technologies
4. Stability — Veterinary storage conditions may differ from human pharmaceutical standards, requiring extended stability testing

Aligned Machinery specializes in pharmaceutical manufacturing equipment that supports diverse formulation requirements, including oral disintegrating film (ODF) production lines and transdermal patch manufacturing systems. These technologies enable pharmaceutical manufacturers to develop veterinary-specific dosage forms that improve compliance and therapeutic outcomes.

Packaging and Dosing Device Adaptations

Veterinary packaging must accommodate species-specific dosing requirements, owner administration ease, and regulatory labeling standards. Multi-dose packaging with calibrated dosing devices, child-resistant but pet-owner-friendly closures, and clear species-specific labeling are essential for market success.

Market Opportunities and Commercial Considerations

Global Veterinary Pharmaceutical Market Growth

The global veterinary medicine market is projected to reach $113.80 billion by 2033, growing at a CAGR of 10.57% from 2026^[6]. This growth is driven by increasing pet ownership, rising pet healthcare expenditure, growing awareness of animal health, and expansion of veterinary services in emerging markets.

Regional Market Highlights:

• Asia-Pacific — Fastest-growing region with 9.03% CAGR from 2026–2035, driven by rising livestock production and companion animal ownership^[7]
• China — Market growing from $5.11 billion in 2026 to $9.29 billion by 2032, representing an 82% increase^[2]
• United States — Pet medications market surpassed $12 billion in 2022 with continued steady growth expected^[8]

Therapeutic Areas with High Repurposing Potential

Oncology, pain management, cardiovascular disease, and infectious disease represent the highest-value therapeutic areas for veterinary drug repurposing. Companion animal oncology alone presents significant opportunities, as cancer treatment options for dogs and cats remain limited compared to human medicine. The successful repurposing of COX-2 inhibitors for canine cancer treatment demonstrates the clinical and commercial viability of this approach^[3].

Intellectual Property and Market Exclusivity

Patent-based and regulatory-based market exclusivity mechanisms protect investment in veterinary drug repurposing. Second medical use patents can provide protection for new veterinary indications of existing human drugs, while regulatory data exclusivity periods (5 years in the US, up to 10 years in the EU) prevent generic competition during the exclusivity period.

Off-patent human drugs offer particularly attractive repurposing opportunities, as manufacturers can leverage established safety profiles without patent infringement concerns while securing new veterinary-specific patents for formulations, dosing regimens, or combination products.

One Health Approach to Drug Repurposing

Integrating Human and Veterinary Drug Innovation

The One Health concept recognizes the interconnection between human, animal, and environmental health, creating opportunities for bidirectional drug repurposing between human and veterinary medicine. Diseases affecting both humans and animals—such as cancer, diabetes, cardiovascular disease, and infectious diseases—benefit from shared research, clinical data, and therapeutic development.

Proposed One Health Drug Repositioning Platform:

A conceptually new platform integrating human and veterinary drug repositioning into a unified innovation space would facilitate:

1. Shared Data Resources — Pooling pharmacological, toxicological, and clinical data across species
2. Collaborative Research — Joint human-veterinary research initiatives in oncology, infectious disease, and chronic conditions
3. Regulatory Harmonization — Streamlined approval pathways recognizing cross-species data validity
4. Manufacturing Synergies — Shared production facilities and quality systems for human and veterinary products

Aligned Machinery supports this integrated approach by providing pharmaceutical manufacturing equipment suitable for both human and veterinary drug production, enabling manufacturers to leverage existing infrastructure for cross-species product development.

Strategic Implementation Roadmap

Step-by-Step Approach to Human-to-Veterinary Drug Repurposing

Step 1: Candidate Selection and Feasibility Assessment

Identify human drugs with veterinary therapeutic potential based on:

• Mechanism of action relevance to veterinary diseases
• Established safety profile in humans
• Patent status and intellectual property landscape
• Market size and commercial viability
• Existing off-label veterinary use data

Step 2: Regulatory Strategy Development

Determine optimal regulatory pathway (NADA, ANADA, EU centralized/decentralized) based on:

• Target animal species (companion vs. food-producing)
• Geographic market priorities
• Existing data availability
• Competitive landscape

Step 3: Gap Analysis and Data Generation

Conduct comprehensive gap analysis comparing existing human drug data with veterinary regulatory requirements:

• Species-specific pharmacokinetics and metabolism studies
• Target animal safety and efficacy trials
• Residue studies for food-producing animals
• Environmental risk assessment

Step 4: Formulation Development and Manufacturing

Adapt formulation for veterinary use:

• Species-appropriate excipients and flavoring
• Dosage form optimization for animal administration
• Packaging and dosing device design
• Manufacturing process validation

Aligned Machinery’s ODF production lines, transdermal patch manufacturing systems, and flexible pharmaceutical equipment enable efficient formulation development and scale-up for veterinary-specific dosage forms.

Step 5: Regulatory Submission and Approval

Prepare and submit regulatory applications:

• Compile comprehensive dossier with all required sections
• Engage with regulatory authorities through pre-submission meetings
• Respond to regulatory questions and deficiency letters
• Obtain marketing authorization

Step 6: Market Launch and Pharmacovigilance

Execute commercial launch strategy:

• Veterinarian education and training programs
• Distribution channel establishment
• Post-market safety monitoring and adverse event reporting
• Ongoing regulatory compliance and lifecycle management

FAQ

What is the typical timeline for repurposing a human drug for veterinary use?

The timeline for human-to-veterinary drug repurposing typically ranges from 3–5 years through the FDA NADA process, compared to 10–15 years for de novo drug development^[3]. The EU Regulation 2019/6 pathway may require 2–4 years depending on the complexity of gap analysis and data generation requirements^[4]. Generic pathways through ANADA can be completed in 1–2 years if bioequivalence to an approved veterinary drug can be demonstrated.

What are the main cost advantages of drug repurposing versus de novo development?

Drug repurposing reduces development costs by 40–60% compared to de novo drug development^[3]. While de novo human drug development costs reached $2.558 billion in capitalized costs^[3], repurposing leverages existing safety data, manufacturing processes, and regulatory knowledge, significantly reducing preclinical and early clinical trial expenses. For veterinary applications with smaller market sizes, this cost reduction makes development economically viable.

Can off-patent human drugs be repurposed for veterinary use without patent infringement?

Yes, off-patent human drugs can be repurposed for veterinary use without infringing the original human drug patent. However, manufacturers can secure new veterinary-specific patents for second medical use, novel formulations, species-specific dosing regimens, or combination products. These new patents provide market exclusivity for the veterinary indication while the original human drug remains off-patent.

What manufacturing equipment modifications are needed for veterinary drug production?

Manufacturing equipment for veterinary drugs must accommodate species-specific formulation requirements, including different excipients, palatability enhancers, and dosage forms. Flexible pharmaceutical equipment such as Aligned Machinery’s ODF production lines and transdermal patch systems enable efficient formulation adjustments without major capital investment. Key modifications include dosing accuracy for weight-based administration, packaging systems for veterinary-specific containers, and quality control systems adapted for veterinary regulatory requirements.

How does environmental risk assessment differ between human and veterinary drugs?

Environmental risk assessment (ERA) for veterinary drugs is more comprehensive than for human drugs due to direct environmental release through animal excretion^[4]. Veterinary ERA evaluates impacts on soil, water, and non-target organisms, particularly for drugs used in food-producing animals. This assessment is mandatory under EU Regulation 2019/6 and influences approval decisions, requiring manufacturers to demonstrate environmental safety or implement risk mitigation measures.

Conclusion: Seizing the Veterinary Drug Repurposing Opportunity

The convergence of growing veterinary pharmaceutical markets, established regulatory pathways, and proven cost advantages positions human-to-veterinary drug repurposing as a strategic opportunity for pharmaceutical manufacturers in 2026 and beyond. With the global veterinary medicine market projected to reach $113.80 billion by 2033^[6] and regional markets such as China experiencing 82% growth through 2032^[2], the commercial case for repurposing is compelling.

Successful implementation requires strategic planning across regulatory pathways, formulation development, manufacturing capabilities, and market access strategies. Pharmaceutical manufacturers that leverage existing drug portfolios, invest in species-specific clinical data, and partner with specialized equipment suppliers like Aligned Machinery will be best positioned to capture this growing market opportunity.

The One Health approach to drug repurposing offers additional advantages by integrating human and veterinary drug innovation, creating synergies in research, development, and manufacturing that benefit both human and animal health outcomes. As regulatory frameworks continue to evolve and market demand accelerates, human-to-veterinary drug repurposing represents not just a cost-effective development strategy, but a pathway to addressing critical unmet medical needs in veterinary medicine.

For pharmaceutical manufacturers seeking to enter or expand in the veterinary market, now is the time to evaluate repurposing opportunities, develop regulatory strategies, and invest in the manufacturing capabilities that will define success in this dynamic and growing industry.

References

[1] The Business Research Company, “Veterinary Pharmaceuticals Global Market Report,” 2026. “The veterinary pharmaceuticals market size has grown strongly in recent years. It will grow from $34.92 billion in 2025 to $37.01 billion in 2026 at a compound annual growth rate of 6.0%.” https://www.thebusinessresearchcompany.com/report/veterinary-pharmaceuticals-global-market-report

[2] MarkNtel Advisors, “China Veterinary Medicine Market Share Insights 2026-32,” 2026. “The China Veterinary Medicine Market is valued at USD 4.89 billion in 2025, rising to USD 5.11 billion in 2026, and projected to reach USD 9.29 billion by 2032.” https://www.marknteladvisors.com/research-library/china-veterinary-medicine-market

[3] National Center for Biotechnology Information, “Some Aspects and Convergence of Human and Veterinary Drug Repositioning,” 2024. “Drug repurposing reduces development costs by 40–60% and accelerates time-to-market by 5–10 years compared to de novo drug development. The capitalized cost of developing a new human drug reached $2.558 billion.” https://pmc.ncbi.nlm.nih.gov/articles/PMC11433938/

[4] Medfiles Group, “Repurposing human medicines for veterinary use: key considerations,” 2025. “EU Regulation 2019/6 establishes comprehensive framework differences in CMC, pharmacovigilance, and environmental risk assessment. ERA for VMP is more comprehensive due to direct environmental release through animal excretion.” https://medfilesgroup.com/repurposing-human-medicines-for-veterinary-use/

[5] GM Insights, “Companion Animal Drugs Market Size & Share 2026-2035,” 2026. “The global companion animal drugs market was valued at USD 26.8 billion in 2025. The market is expected to grow from USD 28.8 billion in 2026 to USD 51.1 billion by 2035.” https://www.gminsights.com/industry-analysis/companion-animal-drugs-market

[6] Grand View Research, “Veterinary Medicine Market Size | Industry Report, 2033,” 2026. “The global veterinary medicine market is expected to grow at a compound annual growth rate of 10.57% from 2026 to 2033 to reach USD 113.80 billion by 2033.” https://www.grandviewresearch.com/industry-analysis/veterinary-medicine-market

[7] SNS Insider, “Veterinary Medicine Market Size & Share Report, 2035,” 2026. “The Asia-Pacific veterinary medicine market is expected to grow at the fastest CAGR of 9.03% from 2026 to 2035, driven by rising livestock production and companion animal ownership.” https://www.snsinsider.com/reports/veterinary-medicine-market-8934

[8] Business Wire, “United States Pet Medications Markets, 2022-2023 & 2027,” 2023. “The pet medications market surpasses $12 billion for the first time in 2022, and the publisher expects growth to continue at a modest but steady pace.” https://www.businesswire.com/news/home/20230801658176/en/United-States-Pet-Medications-Markets-2022-2023-2027

#VeterinaryPharmaceuticals #DrugRepurposing #AnimalHealth #PharmaceuticalManufacturing #RegulatoryAffairs #OneHealth #PetMedicine #VeterinaryMedicine #PharmaceuticalInnovation #CompanionAnimalHealth